Ulonivirine

Ulonivirine (MK-8507) is an orally active non-nucleoside reverse transcriptase inhibitor with high antiviral activity. Ulonivirine can be used for the research of HIV-1 infection[1][2][3][4].

Product Specifications

CAS Number

[1591823-76-5]

Product Name Alternative

MK-8507

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

HIV; Reverse Transcriptase

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/ulonivirine.html

Purity

98.61

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

N#CC1=CC(Cl)=CC(OC2=C(C(F)(F)F)N=CN(CC3=NNC(C(C(F)(F)F)=C3)=O)C2=O)=C1

Molecular Formula

C18H8ClF6N5O3

Molecular Weight

491.73

Precautions

H302, H315, H319

References & Citations

[1]Schürmann D, et al. Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week. J Acquir Immune Defic Syndr. 2022 Feb 1;89 (2) :191-198.|[2]Gillespie SW, et al. Islatravir: evaluation of clinical development for HIV and HBV. Expert Opin Investig Drugs. 2024 Feb;33 (2) :85-93. |[3]Ankrom W, et al. Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV. Antimicrob Agents Chemother. 2021 Nov 17;65 (12) :e0093521. |[4]Gillespie G, et al. Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK-8507, an Investigational, Oral, Once-Weekly Nonnucleoside Reverse Transcriptase Inhibitor. J Clin Pharmacol. 2022 Feb;62 (2) :199-205.